Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Completed · Phase 1
Conditions studied: Malignant Glioma, Glioblastoma, Gliosarcoma
In brief
A Phase I, open-label, non-randomized, sequential dose escalation cohort trial of the safety, tolerability, and maximum tolerated dose (MTD) of AP23573 when administered intravenously as a 30-minute infusion, once daily for five days, repeated every two weeks, to patients with progressive or recurrent malignant glioma.
Key facts
- Study ID
- NCT00087451
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 11
- Starts
- 2004-07-01
- Expected to finish
- 2005-11-01
- Last updated by the study team
- 2015-08-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Center For Neuro-Oncology, Dana Farber Cancer Institute — Boston, Massachusetts, United States
- The Brain Tumor Center at Duke, Duke University Medical Center — Durham, North Carolina, United States
- Brain Tumor Institute, The Cleveland Clinic — Cleveland, Ohio, United States
- M.D. Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.